AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 163 min read$ADM

September Syndrome in Full Swing: 3 Picks to Safeguard Your Portfolio

September historically underperforms for U.S. equities, with indices like S&P 500, Dow, and Nasdaq showing average declines. This year, factors like high oil prices, rising Treasury yields, and Fed rate hike expectations add to market concerns. Zacks Investment Research recommends Archer-Daniels-Midland (ADM), Amgen (AMGN), and Sunoco LP (SUN) as defensive stocks with strong fundamentals and growth prospects.

Original reporting
theglobeandmail.com
Published Sep 16, 2026, 1:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
September Syndrome in Full Swing: 3 Picks to Safeguard Your Portfolio — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$ADMBullishMed
01

Why it matters

Guidance upgrades for ADM, AMGN, and SUN provide fresh, material information that could drive short‑term price appreciation.

02

Market read

Guidance upgrades for three defensive stocks may attract capital amid a seasonally weak market, offering modest upside opportunities.

03

What to watch

Rising oil prices and higher Treasury yields could offset earnings benefits for these low‑beta stocks.

Relevance 6/10Novelty 6/10Timing: September 16 2026 (today)

Background

The article highlights September’s historically weak performance and recommends three low‑beta, high‑yield stocks with upgraded guidance.

Company-level read

Ticker impact

$ADMBullishHigh confidence
Context

Archer-Daniels-Midland raised its 2026 adjusted earnings guidance to $5.15‑$5.60 per share, up from $4.15‑$4.70.

Expected impact

Potential upside of 5‑10% over the next few weeks.

Evidence & confidence

Guidance lift is a primary disclosure with material dollar scale for a large cap agribusiness.

$AMGNBullishHigh confidence
Context

Amgen increased its 2026 revenue guidance to $38.2‑$39.4 bn and adjusted earnings guidance to $22.30‑$23.50 per share.

Expected impact

Possible 4‑8% rally if market digests the upgrade.

Evidence & confidence

Guidance upgrade for a mega‑cap biotech is a fresh, material fact.

$SUNBullishHigh confidence
Context

Sunoco raised its 2026 adjusted EBITDA guidance to $3.5‑$3.7 bn, up $400 m from prior range.

Expected impact

Likely 3‑6% upside in the short term.

Evidence & confidence

EBITDA guidance increase is a primary disclosure for a mid‑cap energy distributor.

Market effects

Sector

Defensive, low‑beta consumer staples and health‑care may attract capital as September historically drags equities.

Regional

U.S. equity market bias toward defensive stocks could temper broader index declines.

Global

Guidance upgrades may influence global commodity‑linked exposure (e.g., bio‑fuel demand for ADM).

Counterpoint

What could challenge this read

September historically hurts equities; the guidance upgrades may be priced in quickly, limiting upside.

Key entities

  • company
    Archer-Daniels-Midland Co.

    Agribusiness firm with raised 2026 earnings guidance.

  • company
    Amgen Inc.

    Biotech with increased 2026 revenue and earnings guidance.

  • company
    Sunoco LP

    Fuel distributor with higher 2026 EBITDA guidance.

Read at source← All news

Related articles

SEP 17
$AMGNLow

Line ITP Market With New Phase 3 Romiplostim Trial

Amgen (AMGN) is conducting a Phase 3 trial comparing romiplostim plus prednisone against prednisone alone for newly diagnosed primary immune thrombocytopenia. The study aims to improve platelet control and reduce steroid exposure. A positive result could expand romiplostim's market and strengthen Amgen's hematology portfolio. The trial is ongoing, with recruitment active.

tipranks.com2 min
SEP 15
$CNCMed

2 Non-AI Giants to Buy on Solid Guidance and Lucrative Valuation

Centene Corp. (CNC) and Archer-Daniels-Midland Co. (ADM) are highlighted for strong performance and attractive valuations. CNC expects 2026 revenues of $173-$177B and adjusted EPS over $4.80, with a forward P/E of 13.58X. ADM raised 2026 adjusted earnings guidance to $5.15-$5.60 per share, with a forward P/E of 16.60X.

tradingview.com3 min
SEP 15
$AMGNLow

FDA reduces monitoring time for Amgen’s Imdelltra infusions

The FDA updated Amgen's Imdelltra (tarlatamab-dlle) prescribing info, reducing monitoring time for the first two doses to 6-8 hours from 22-24 hours for ES-SCLC patients post-chemotherapy. Subsequent doses retain prior monitoring times. Amgen states this may simplify care and reduce patient time in healthcare settings. Imdelltra is a targeted immunotherapy for ES-SCLC, approved conditionally in the UK in January 2025.

pharmaceutical-technology.com1 min
SEP 15
$AMGNMed

As Fed hike looms, AI strategy’s mid-cap picks draw attention with 580% gain

U.S. 10-year Treasury yields hit 5%, highest since 2007, ahead of Fed decision with 90% chance of a 25-basis-point hike. Investing.com's Mid-Cap Movers strategy gained 580.7% since 2013, outperforming S&P MidCap 400. Top performers include Commvault (CVLT, +8.5%), Insight Enterprises (NSIT, +5.0%), and Wingstop (WING, +4.7%). Lennox International (LII) downgraded to Hold, Amgen (AMGN) FDA approval for Imdelltra.

investing.com2 min